Cord blood ads have hypnotic effect

Share this article:
An unconventional technique led to the counter-intuitive insight behind a campaign for Cord Blood Registry (CBR).

Despite high awareness—around 90%—and acceptance of the need for cord blood banking, fewer than 5% of expectant moms bank. CBR knew it faced an action problem—not an awareness problem. “In a situation where 95% of cord blood is disposed of as medical waste, our competition is really the trash can,” said Dave Zitlow, SVP corporate communications at CBR.

The company thought cost was the most likely culprit, but that rationale didn't quite make sense, since the bank's primary target was Range Rover-driving “Yoga moms.” CBR's agency, Draftfcb, brought in an addition specialist to get under their skin. He put his subjects in a light state of hypnosis and asked them to draw what they were feeling when they decided not to bank.
“With unbelievable consistency, they kept drawing a circle around their heart connecting to the child, rather than the umbilical cord,” said Mike Rutstein, EVP director of consumer healthcare at Draftfcb.

The women, they concluded, identified love, and not the cord, as the life-giver, and could not conceive of sickness while giving life. So the campaign, in Webisodes, in-office materials and print ads running in women's and pregnancy mags, eschewed a disease focus in favor of tales of heroism, telling the stories of moms who saved lives—of their children or others through donated cord blood. In the print ads, they wore capes. “We flipped this from being about sickness and disease to being about hope and heroism,” said Rutstein.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.